Physician profile
Robert E Brass
NPI 1326003682
$46,210.57
in general payments reported to CMS, 2019-2025
27 companies · $5,691 in 2025
The $5,691 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $411 · 2021: $586 · 2022: $6,077 · 2023: $17K · 2024: $15K · 2025: $5,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,288 · Food and Beverage: $7,017 · Consulting Fee: $6,588 · Travel and Lodging: $2,197 · Education: $16.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $13,656.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,287.50 |
| Food and Beverage | $7,017.09 |
| Consulting Fee | $6,587.50 |
| Travel and Lodging | $2,197.00 |
| Education | $16.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $21,871.70 | 2019-2023 | Tepezza |
| Amgen INC. | $17,601.70 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $1,663.16 | 2019-2025 | Clareon, Argos, Rocklatan |
| Bausch & Lomb Americas INC. | $667.26 | 2022-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Sun Pharmaceutical Industries INC. | $553.11 | 2019-2025 | Cequa |
| Ocular Therapeutix, INC. | $471.39 | 2019-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $429.61 | 2024-2025 | Xdemvy |
| Abbvie INC. | $360.81 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $349.09 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $304.08 | 2025 | |
| Mallinckrodt Hospital Products INC. | $303.88 | 2021-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $251.39 | 2019-2021 | |
| Sight Sciences, INC. | $244.39 | 2019-2023 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $193.82 | 2019-2023 | |
| Allergan, INC. | $193.05 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $152.45 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.92 | 2019-2021 | |
| Dompe US, INC. | $124.37 | 2020-2025 | Oxervate |
| Biotissue Holdings INC. | $87.98 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $74.83 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $32.98 | 2019-2023 | Flarex |
| Eyepoint US, INC. | $29.91 | 2019 | |
| Ani Pharmaceuticals, INC. | $28.68 | 2025 | Purified Cortrophin Gel |
| Thea Pharma INC. | $24.95 | 2025 | Iyuzeh |
| Ivantis, INC | $23.57 | 2021 | |
| Omeros Corporation | $16.01 | 2020 | |
| Rayner Intraocular Lenses Limited | $15.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.